Sangamo Therapeutics Deal History & Licensing Activity
Sangamo Therapeutics is a biotech headquartered in US. Over the past three years, Sangamo Therapeutics has been involved in 5 licensing and acquisition transactions, with a primary focus on Gene Therapy (8 deals). The company currently has 7 active clinical trials, primarily in Neurology.
Deals (12mo)
3
Active Trials
7
Top Modality
Gene Therapy
Focus Area
Neurology
Sangamo Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sangamo Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| isaralgagene civaparvovec / ST-920 | PTC Therapeutics | Gene Therapy | Phase 1 | acquisition | Aug 12, 2026 |
| Capsid delivery, zinc finger, and MINT platforms; ST-506 prion-disease program | Eli Lilly and Company | Gene Therapy | Preclinical | acquisition | Jun 23, 2026 |
| isaralgagene civaparvovec (ST-920) | Astellas Pharma Inc. | Gene Therapy | Phase 1 | acquisition | Jun 23, 2026 |
Sangamo Therapeutics Pipeline Focus
Therapeutic areas and modalities where Sangamo Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Sangamo Therapeutics Strategic Signals
Key indicators of Sangamo Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Sangamo Therapeutics Clinical Pipeline
Sangamo Therapeutics has 7 active clinical trials across 3 development phases.
4
Unknown
1
Phase 1
2
Phase 1/2
See How Your Asset Matches Sangamo Therapeutics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Sangamo Therapeutics Licensing & Deal Activity
Sangamo Therapeutics is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Sangamo Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sangamo Therapeutics include Neurology (4 deals and trials), Rare Disease (3 deals and trials), Metabolic (2 deals and trials), and Rare Disease (2 deals and trials). In terms of modality, Sangamo Therapeutics has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sangamo Therapeutics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Sangamo Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.